Abstract
Acute alcohol consumption has adverse effects in kidney, that causes kidney injury and disease, which is usually accompanied by oxidation and inflammation. Scutellarin (SCU) is the major effective ingredient of breviscapine and its anti-inflammation and antioxidant efficacy has been reported before. The present study is to check the protective effective of scutellarin as therapeutic medicine against alcohol-induced inflammation and oxidative stress leading to acute kidney injury (AKI). The AKI model was established by giving 50% ethanol (12 mL/kg) via lavage. Kidney tissues were collected and used for histopathology analysis, biochemical assays, qRT-PCR tests. The therapeutic effects of SCU were evaluated by observing pathological changes from HE-stained kidney tissues. Additionally, the anti-inflammation activity of SCU was evaluated by measuring the relative mRNA expressing levels of Tnf-α , Il-1β , Il-6 and the activity of iNOS. The antioxidant capacity was assessed by measuring the lipid peroxidation marker MDA, antioxidant enzymes activity of SOD, CAT and GSH-Px. The results suggested that serious swelling and damage occurred in the renal tubular epithelium of alcohol intake group, accompanying with glomerular atrophy, necrosis and increase of inflammatory cells. SCU treatment significantly relieved the damage of diseased renal tubular epithelium and glomerular, and less inflammatory cell emerged. The inflammation cytokines expressing levels were elevated and oxidative stress index decreased after alcohol intake compared to the control group. In conclusion, inflammation and oxidative stress occur in the kidney after acute and massive alcohol intake, SCU exhibits protective roles via its anti-inflammatory and antioxidant activity in AKI.
Full text
